Advertisement
Mr. Tang Hui Tian, Chairman and CEO of CBT, stated that "Our Company is inthe midst of growth and expansion in Guangxi province, and given our status asa U.S.-traded Company and plans to up-list to a national exchange in the nearfuture, we feel Harbinger Research's coverage of CBT comes at an excellenttime for CBT and its investors. We believe our company and industry willcontinue to demonstrate robust growth for years to come, as per-capitadisposable income and government-driven pharmaceutical spending in Chinacontinue to grow."
Advertisement
Brian R. Connell, CFA, a Harbinger Research Senior Analyst, stated that,"We are excited to initiate coverage on China Baicaotang, which we believe issignificantly undervalued on both a relative and absolute basis. We expect thepharmaceutical industry to remain strong in China for the foreseeable future,clearly benefiting all provincial industry leaders, including ChinaBaicaotang."
To view Harbinger Research's coverage initiation on China BaicaotangMedicine, Ltd., rated by Brian R. Connell, CFA, please click on the followinglink: http://www.harbingerresearch.com/link/13/253/CNBI
About China Baicaotang Medicine, Ltd.
China Baicaotang is a vertically-integrated pharmaceutical company thatoperates in the Guangxi Province of China. The Company's three operatingsubsidiaries include a drug and herbal remedy manufacturing company, apharmaceutical distributor that carries over 8,000 products, and a retaildrugstore chain with 66 stores throughout the Guangxi province. The companyis an emerging leader in this region of the PRC, and its shares currentlytraded on the OTC:BB under the symbol CNBI. Learn morehttp://www.china-bct.com .
About Harbinger Research, LLC
Harbinger Research is an independent equity research that employs aresearch team consisting entirely of CFA charter holders and follows a numberof companies across a wide variety of industries. Harbinger Research makes allof its reports available through its website athttp://www.harbingerresearch.com , and also distributes content through avariety of partners, including InvestorsInsight Publishing, and through mostmajor financial portals.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statementswithin the meaning of the Private Securities Litigation Reform Act of 1995.When used in this press release, the words "anticipate," "believe,""estimate," "may," "intend," "expect" and similar expressions identify suchforward-looking statements. Actual results, performance or achievements coulddiffer materially from those contemplated, expressed or implied by theforward-looking statements contained herein. These forward-looking statementsare based largely on the expectations of the Company and are subject to anumber of risks and uncertainties. These include, but are not limited to,risks and uncertainties associated with: the impact of economic, competitiveand other factors affecting the Company and its operations, markets, product,and distributor performance, the impact on the national and local economiesresulting from terrorist actions, and U.S. actions subsequently; and otherfactors detailed in reports filed by the Company.For more information, please contact: China Baicaotang Medicine, Ltd. Investor Contact: Shelly Zhang Chief Financial Officer China Baicaotang Medicine Limited Email: [email protected] Tel: +86-772-363-8318 Web: http://www.china-bct.com
SOURCE China Baicaotang Medicine Ltd.
